Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review

被引：37
作者：
Camus, Baptiste [1 ,2 ]
Cottereau, Anne-Segolene [2 ,3 ]
Palmieri, Lola-Jade [1 ,2 ]
Dermine, Solene [1 ,2 ]
Tenenbaum, Florence [3 ]
Brezault, Catherine [1 ,2 ]
Coriat, Romain [1 ,2 ]
机构：
[1] Cochin Hosp, AP HP Ctr, Gastroenterol & Digest Oncol Unit, 27 Rue Faubourg St Jacques, F-75014 Paris, France
[2] Univ Paris, Fac Med, F-75006 Paris, France
[3] Cochin Hosp, AP HP Ctr, Dept Nucl Med, 27 Rue Faubourg St Jacques, F-75014 Paris, France
来源：
JOURNAL OF CLINICAL MEDICINE | 2021年 / 10卷 / 06期
关键词：
neuroendocrine tumors; neoplasm metastasis; PRRT; peptide receptor radionuclide therapy; gastroenteropancreatic tumor; pulmonary tumor; RADIOLABELED SOMATOSTATIN ANALOG; TYR(3) OCTREOTATE; LU-177-DOTATATE; EFFICACY; LU-177-OCTREOTATE; FEASIBILITY; TOXICITY; SURVIVAL; NEN; G3;
D O I：
10.3390/jcm10061267
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are Y-90-DOTATOC and Lu-177-DOTATATE. Radio-peptides have been used for several years in the treatment of advanced neuroendocrine tumors. Recently, the randomized Phase III study NETTER-1 compared(177)Lu-DOTATATE versus high-dose (double-dose) octreotide LAR in patients with metastatic midgut neuroendocrine tumors, and demonstrated its efficacy in this setting. Strong signals in favor of efficiency seem to exist for other tumors, in particular for pancreatic and pulmonary neuroendocrine tumors. This focus on radionuclide therapy in gastroenteropancreatic and pulmonary neuroendocrine tumors addresses the treatment modalities, the validated and potential indications, and the safety of the therapy.
引用
收藏
页码：1 / 18
页数：15
相关论文
共 45 条
  • [1] Advanced Accelerator Applications, 2020, RANDOMIZED OPEN LABE
  • [2] Bodei L, 2020, LANCET ONCOL, V21, pE431, DOI 10.1016/S1470-2045(20)30323-5
  • [3] Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer
    Bodei, Lisa
    Kwekkeboom, Dik J.
    Kidd, Mark
    Modlin, Irvin M.
    Krenning, Eric P.
    [J]. SEMINARS IN NUCLEAR MEDICINE, 2016, 46 (03) : 225 - 238
  • [4] Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors
    Bodei, Lisa
    Kidd, Mark
    Paganelli, Giovanni
    Grana, Chiara M.
    Drozdov, Ignat
    Cremonesi, Marta
    Lepensky, Christopher
    Kwekkeboom, Dik J.
    Baum, Richard P.
    Krenning, Eric P.
    Modlin, Irvin M.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 (01) : 5 - 19
  • [5] Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study
    Bodei, Lisa
    Cremonesi, Marta
    Grana, Chiara M.
    Fazio, Nicola
    Iodice, Simona
    Baio, Silvia M.
    Bartolomei, Mirco
    Lombardo, Dario
    Ferrari, Mahila E.
    Sansovini, Maddalena
    Chinol, Marco
    Paganelli, Giovanni
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (12) : 2125 - 2135
  • [6] Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
    Brabander, Tessa
    van der Zwan, Wouter A.
    Teunissen, Jaap J. M.
    Kam, Boen L. R.
    Feelders, Richard A.
    de Herder, Wouter W.
    van Eijck, Casper H. J.
    Franssen, Gaston J. H.
    Krenning, Eric P.
    Kwekkeboom, Dik J.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4617 - 4624
  • [7] High risk of myelodysplastic syndrome and acute myeloid leukemia after 177Lu-octreotate PRRT in NET patients heavily pretreated with alkylating chemotherapy
    Brieau, Bertrand
    Hentic, Olivia
    Lebtahi, Rachida
    Palazzo, Maxime
    Ben Reguiga, Makrem
    Rebours, Vinciane
    Maire, Frederique
    Hammel, Pascal
    Ruszniewski, Philippe
    Fenaux, Pierre
    [J]. ENDOCRINE-RELATED CANCER, 2016, 23 (05) : L17 - L23
  • [8] Capello A, 2003, J NUCL MED, V44, P98
  • [9] Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
    Carlsen, Esben Andreas
    Fazio, Nicola
    Granberg, Dan
    Grozinsky-Glasberg, Simona
    Ahmadzadehfar, Hojjat
    Grana, Chiara Maria
    Zandee, Wouter T.
    Cwikla, Jaroslaw
    Walter, Martin A.
    Oturai, Peter Sandor
    Rinke, Anja
    Weaver, Andrew
    Frilling, Andrea
    Gritti, Sara
    Arveschoug, Anne Kirstine
    Meirovitz, Amichay
    Knigge, Ulrich
    Sorbye, Halfdan
    [J]. ENDOCRINE-RELATED CANCER, 2019, 26 (02) : 227 - 239
  • [10] Radionuclide Therapy for Neuroendocrine Tumors
    Cives, Mauro
    Strosberg, Jonathan
    [J]. CURRENT ONCOLOGY REPORTS, 2017, 19 (02)
12345